Tag: Eluminex Biosciences Limited

Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema...

EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6RImprovements in Visual Acuity and Retinal Edema Observed at All Dose LevelsNo Safety Issues Observed Following a...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsEluminex Biosciences Limited

PUDO Inc announces earnings call for Q1 FY 2026 – save the date

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe

Tag: Eluminex Biosciences Limited

Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us